Original Article

You have full text access to this OnlineOpen article

Dose intensity and hematologic toxicity in older breast cancer patients receiving systemic chemotherapy

  1. Michelle Shayne MD1,
  2. Eva Culakova PhD, MS2,
  3. Debra Wolff MS, PCNP2,
  4. Marek S. Poniewierski MD, MS2,
  5. David C. Dale MD3,
  6. Jeffrey Crawford MD2,
  7. Gary H. Lyman MD, MPH2,†,*

Article first published online: 11 AUG 2009

DOI: 10.1002/cncr.24560

Issue

Cancer

Cancer

Volume 115, Issue 22, pages 5319–5328, 15 November 2009

Additional Information

How to Cite

Shayne, M., Culakova, E., Wolff, D., Poniewierski, M. S., Dale, D. C., Crawford, J. and Lyman, G. H. (2009), Dose intensity and hematologic toxicity in older breast cancer patients receiving systemic chemotherapy. Cancer, 115: 5319–5328. doi: 10.1002/cncr.24560

Author Information

  1. 1

    Department of Medicine, University of Rochester and the James P Wilmot Cancer Center, Rochester, New York

  2. 2

    Department of Medicine, Duke University and the Duke Comprehensive Cancer Center, Durham, North Carolina

  3. 3

    Department of Medicine, University of Washington, Seattle, Washington

  1. †

    Fax: (919) 681-7488

*Duke University, 2424 Erwin Road, Suite 205, Durham, NC 27705

Publication History

  1. Issue published online: 3 NOV 2009
  2. Article first published online: 11 AUG 2009
  3. Manuscript Accepted: 27 APR 2009
  4. Manuscript Revised: 23 MAR 2009
  5. Manuscript Received: 5 NOV 2008

SEARCH

SEARCH BY CITATION

ARTICLE TOOLS

View Full Article (HTML) Get PDF (234K)

References

  • 1
    Yancik R, Ries LA. Aging and cancer in America. Demographic and epidemiologic perspectives. Hematol Oncol Clin North Am. 2000; 14: 17-23.
  • 2
    Early Breast Cancer Trialists' Collaborative Group. Polychemotherapy for early breast cancer: an overview of the randomised trials. Lancet. 1998; 352: 930-942.
  • 3
    Muss HB, Woolf S, Berry D, et al. Adjuvant chemotherapy in older and younger women with lymph node-positive breast cancer. JAMA. 2005; 293: 1073-1081.
  • 4
    Crivellari D, Bonetti M, Castiglione-Gertsch M, et al. Burdens and benefits of adjuvant cyclophosphamide, methotrexate, and fluorouracil and tamoxifen for elderly patients with breast cancer: the International Breast Cancer Study Group Trial VII. J Clin Oncol. 2000; 18: 1412-1422.
  • 5
    Bonadonna G, Zambetti M, Valagussa P, et al. Adjuvant cyclophosphamide, methotrexate, and fluorouracil in node-positive breast cancer: the results of 20 years of follow-up. N Engl J Med. 1995; 332: 901-906.
  • 6
    Budman DR, Berry DA, Cirrincione CT, et al. Dose and dose intensity as determinants of outcome in the adjuvant treatment of breast cancer. J Natl Cancer Inst. 1998; 90: 1205-1211.
  • 7
    Chang J. Chemotherapy dose reduction and delay in clinical practice: evaluating the risk to patient outcome in adjuvant chemotherapy for breast cancer. Eur J Cancer. 2000; 36( suppl 1): S11-S14.
  • 8
    Piccart MJ, Biganzoli L, Di Leo A. The impact of chemotherapy dose density and dose intensity on breast cancer outcome: what have we learned? Eur J Cancer. 2000; 36( suppl 1): S4-S10.
  • 9
    Lyman GH, Dale DC, Crawford J. Incidence and predictors of low dose-intensity in adjuvant breast cancer chemotherapy: a nationwide study of community practices. J Clin Oncol. 2003; 21: 4524-4531.
  • 10
    Shayne M, Crawford J, Dale DC, Culakova E, Lyman GH. Predictors of reduced dose intensity in patients with early-stage breast cancer receiving adjuvant chemotherapy. Breast Cancer Res Treat. 2006; 100: 255-262.
  • 11
    Shayne M, Culakova E, Poniewierski MS, et al. Dose intensity and hematologic toxicity in older cancer patients receiving systemic chemotherapy. Cancer. 2007; 110: 1611-1620.
    Direct Link:
  • 12
    Hutchins LF, Unger JM, Crowley JJ, Coltman CA Jr, Albain KS. Underrepresentation of patients 65 years of age or older in cancer-treatment trials. N Engl J Med. 1999; 341: 2061-2067.
  • 13
    Eifel P, Axelson JA, Costa J, et al. National Institutes of Health Consensus Development Conference Statement: adjuvant therapy for breast cancer, November 1-3, 2000. J Natl Cancer Inst. 2001; 93: 979-989.
  • 14
    Doyle JJ, Neugut AI, Jacobson JS, Grann VR, Hershman DL. Chemotherapy and cardiotoxicity in older breast cancer patients: a population-based study. J Clin Oncol. 2005; 23: 8597-8605.
  • 15
    Elkin EB, Hurria A, Mitra N, Schrag D, Panageas KS. Adjuvant chemotherapy and survival in older women with hormone receptor-negative breast cancer: assessing outcome in a population-based, observational cohort. J Clin Oncol. 2006; 24: 2757-2764.
  • 16
    Du XL, Key CR, Osborne C, Mahnken JD, Goodwin JS. Discrepancy between consensus recommendations and actual community use of adjuvant chemotherapy in women with breast cancer. Ann Intern Med. 2003; 138: 90-97.
  • 17
    Muss HB, Berry DA, Cirrincione C, et al. Toxicity of older and younger patients treated with adjuvant chemotherapy for node-positive breast cancer: the Cancer and Leukemia Group B Experience. J Clin Oncol. 2007; 25: 3699-3704.
  • 18
    Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987; 40: 373-383.
  • 19
    Mosteller RD. Simplified calculation of body-surface area. N Engl J Med. 1987; 317: 1098.
  • 20
    Chu E, DeVita VT. Physicians' Cancer Chemotherapy Drug Manual 2005. Sudbury, Mass: Jones & Bartlett Publishers; 2005.
  • 21
    Greco FA, Evans WK, Holmes FA, Longo DL, Macdonald JS, Thigpen JT. Handbook of Commonly Used Chemotherapy Regimes: A Quick Reference Guide to More Than 100 Current Cytotoxic Therapies. Chicago, Ill: Precept Press; 1996.
  • 22
    Skeel RT. Handbook of Cancer Chemotherapy. Philadelphia, Pa: Lippincott Williams & Wilkins; 1999.
  • 23
    Amgen. Guide to the Management of Selected Adverse Events Associated With Cancer Chemotherapy. Thousand Oaks, Calif: Amgen; 2000.
  • 24
    Langerak AD, Dreisbach LP. Chemotherapy Regimens and Cancer Care (Vademecum). Bridgewater, NJ: Landes Bioscience; 2001.
  • 25
    Dearnaley DP, Judson I, Root T. Handbook of Adult Cancer Chemotherapy Schedules. King of Prussia, Pa: TMG Health; 2002.
  • 26
    Fischer DS, Knobf MT, Durivage HJ, Beaulieu NJ. The Cancer Chemotherapy Handbook. 6th ed. St. Louis, Mo: CV Mosby; 2003.
  • 27
    Perry MC, Anderson CM, Doll DC, Malhotra V, Shahab N, Wooldridge JE. Companion Handbook to the Chemotherapy Sourcebook. 2nd ed. Philadelphia, Pa: Lippincott Williams & Wilkins; 2004.
  • 28
    Solimando DA. Drug Information Handbook for Oncology: Featuring a Complete Guide to Combination Chemotherapy Regimens. 4th ed. Hudson, Ohio: Lexi-Comp; 2004.
  • 29
    Chrischilles E, Delgado DJ, Stolshek BS, Lawless G, Fridman M, Carter WB. Impact of age and colony-stimulating factor use on hospital length of stay for febrile neutropenia in CHOP-treated non-Hodgkin's lymphoma. Cancer Control. 2002; 9: 203-211.
  • 30
    Kuderer NM, Dale DC, Crawford J, Lyman GH. Impact of primary prophylaxis with granulocyte colony-stimulating factor on febrile neutropenia and mortality in adult cancer patients receiving chemotherapy: a systematic review. J Clin Oncol. 2007; 25: 3158-3167.
  • 31
    Hortobagyi GN, Buzdar AU, Marcus CE, Smith TL. Immediate and long-term toxicity of adjuvant chemotherapy regimens containing doxorubicin in trials at M.D. Anderson Hospital and Tumor Institute. NCI Monogr. 1986;( 1): 105-109.
  • 32
    Bristow MR, Billingham ME, Mason JW, Daniels JR. Clinical spectrum of anthracycline antibiotic cardiotoxicity. Cancer Treat Rep. 1978; 62: 873-879.
  • 33
    Jones SE, Savin MA, Holmes FA, et al. Phase III trial comparing doxorubicin plus cyclophosphamide with docetaxel plus cyclophosphamide as adjuvant therapy for operable breast cancer. J Clin Oncol. 2006; 24: 5381-5387.
  • 34
    Jones S, Holmes F, O'Shaughnessy J, et al. Extended follow-up and analysis by age of the US Oncology Adjuvant trial 9735: docetaxel/cyclophosphamide is associated with an overall survival benefit compared to doxorubicin/cyclophosphamide and is well-tolerated in women 65 or older [abstract]. Breast Cancer Res Treat. 2007; 106: S5. Abstract 12.
  • 35
    Baquet CR, Mishra SI, Commiskey P, Ellison GL, DeShields M. Breast cancer epidemiology in blacks and whites: disparities in incidence, mortality, survival rates and histology. J Natl Med Assoc. 2008; 100: 480-488.
  • 36
    Gillum RF. Epidemiology of hypertension in African American women. Am Heart J. 1996; 131: 385-395.
  • 37
    Gillum RF. Trends in acute myocardial infarction and coronary heart disease death in the United States. J Am Coll Cardiol. 1994; 23: 1273-1277.
  • 38
    National Cancer Institute. Cancer of the Breast: Incidence & Mortality. Bethesda, Md: National Cancer Institute. Available at: http://seer.cancer.gov/statfacts/html/breast.html Accessed July 15, 2008.
  • 39
    Enger SM, Thwin SS, Buist DS, et al. Breast cancer treatment of older women in integrated health care settings. J Clin Oncol. 2006; 24: 4377-4383.
View Full Article (HTML) Get PDF (234K)